أعرض في EDS

Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives

التفاصيل البيبلوغرافية
العنوان: Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives
المؤلفون: Zhu, Yinggang, Monsel, Antoine, Roberts, Jason A, Pontikis, Konstantinos, Mimoz, Olivier, Rello, Jordi, Qu, Jieming, Rouby, Jean-Jacques, European Investigator Network for Nebulized Antibiotics in Ventilator-Associated Pneumonia (ENAVAP), Laterre, Pierre-François
المساهمون: UCL - SSS/IREC/MEDA - Pôle de médecine aiguë, UCL - (SLuc) Service de soins intensifs, Fudan University [Shanghai], Service d'Anesthésie réanimation [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d’Investigation Clinique intégré en Biothérapies et immunologie [AP-HP pitié-salpêtrière, Paris] (CIC-BTi), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], University of Queensland [Brisbane], Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), National and Kapodistrian University of Athens (NKUA), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III [Madrid] (ISC), Vall d’Hebron Research Institute (VHIR), Shanghai Jiao Tong University [Shanghai], Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Institut Català de la Salut, [Zhu Y] Department of Pulmonary and Critical Care Medicine, Hua-Dong Hospital, Fudan University, Shanghai 200433, China. [Monsel A] Multidisciplinary Intensive Care Unit, Department of Anaesthesiology and Critical Care, La Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Medicine Sorbonne University, 75012 Paris, France. Unité Mixte de Recherche (UMR)-S 959, Immunology-Immunopathology-Immunotherapy (I3), Institut National de la Santé et de la Recherche Médicale (INSERM), 75012 Paris, France. Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France. [Roberts JA] Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 75012 Paris, France. University of Queensland Centre for Clinical Research, Faculty of Medicine The University of Queensland, 4006 Brisbane, Australia. Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women’s Hospital, 4006 Brisbane, Australia. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, 30029 Nîmes, France. [Pontikis K] Intensive Care Unit, First Department of Respiratory Medicine, School of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, 15772 Athens, Greece. [Mimoz O] Anaesthesiology and Intensive Care Department, University Hospital of Poitiers, University of Poitiers, 86000 Poitiers, France. [Rello J] Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain. Recerca Clínica/Innovació en la Pneumònia i Sèpsia (CRIPS), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Clinical Research, CHU Nîmes, Université Montpellier-Nîmes, 30029 Nîmes, France, Vall d'Hebron Barcelona Hospital Campus, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP]
المصدر: Microorganisms
Microorganisms, Vol. 9, no.6, p. 1154 [1-25] (2021)
MICROORGANISMS
Microorganisms, MDPI, 2021, 9 (6), pp.1154. ⟨10.3390/microorganisms9061154⟩
Scientia
Microorganisms, Vol 9, Iss 1154, p 1154 (2021)
بيانات النشر: MDPI, 2021.
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, [SDV]Life Sciences [q-bio], Antibiotics, Review, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Gastroenterology, 0302 clinical medicine, Tracheobronchitis, Medicine and Health Sciences, Medicaments antibacterians - Ús terapèutic, Medicine, NOSOCOMIAL PNEUMONIA, 030212 general & internal medicine, colistin, multidrug resistant gram-negative bacteria, Biology (General), nebulized polymyxin, Pneumònia - Tractament, Ventilator-associated pneumonia, ventilator-associated tracheobronchitis, 3. Good health, medicine.anatomical_structure, RESISTANT ACINETOBACTER-BAUMANNII, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents [CHEMICALS AND DRUGS], Other subheadings::Other subheadings::/administration & dosage [Other subheadings], CRITICALLY-ILL PATIENTS, Malalties bacterianes gramnegatives - Tractament, medicine.drug, Microbiology (medical), INHALED COLISTIMETHATE SODIUM, medicine.medical_specialty, infecciones bacterianas y micosis::infección::infección hospitalaria::neumonía asociada al ventilador [ENFERMEDADES], AEROSOLIZED COLISTIN, QH301-705.5, POLYMYXIN-B HEMOPERFUSION, medicine.drug_class, 030106 microbiology, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], phramacokinetic, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos [COMPUESTOS QUÍMICOS Y DROGAS], Microbiology, 03 medical and health sciences, ventilator-associated pneumonia, Pharmacokinetics, Virology, Internal medicine, pharmacodynamics, SYSTEMIC PHARMACOKINETICS, Bacterial Infections and Mycoses::Infection::Cross Infection::Pneumonia, Ventilator-Associated [DISEASES], Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores], PLUS INTRAVENOUS COLISTIN, Lung, nebulized colistimethate sodium, business.industry, Septic shock, SEPTIC SHOCK, PSEUDOMONAS-AERUGINOSA, polylyxin resistance, medicine.disease, Pneumonia, technique of nebulization, Colistin, business
الوصف: Colistin; Phramacokinetic; Technique of nebulization Colistina; Farmacocinètica; Tècnica de nebulització Colistina; Farmacocinético; Técnica de nebulización Clinical evidence suggests that nebulized colistimethate sodium (CMS) has benefits for treating lower respiratory tract infections caused by multidrug-resistant Gram-negative bacteria (GNB). Colistin is positively charged, while CMS is negatively charged, and both have a high molecular mass and are hydrophilic. These physico-chemical characteristics impair crossing of the alveolo-capillary membrane but enable the disruption of the bacterial wall of GNB and the aggregation of the circulating lipopolysaccharide. Intravenous CMS is rapidly cleared by glomerular filtration and tubular excretion, and 20–25% is spontaneously hydrolyzed to colistin. Urine colistin is substantially reabsorbed by tubular cells and eliminated by biliary excretion. Colistin is a concentration-dependent antibiotic with post-antibiotic and inoculum effects. As CMS conversion to colistin is slower than its renal clearance, intravenous administration can lead to low plasma and lung colistin concentrations that risk treatment failure. Following nebulization of high doses, colistin (200,000 international units/24h) lung tissue concentrations are > five times minimum inhibitory concentration (MIC) of GNB in regions with multiple foci of bronchopneumonia and in the range of MIC breakpoints in regions with confluent pneumonia. Future research should include: (1) experimental studies using lung microdialysis to assess the PK/PD in the interstitial fluid of the lung following nebulization of high doses of colistin; (2) superiority multicenter randomized controlled trials comparing nebulized and intravenous CMS in patients with pandrug-resistant GNB ventilator-associated pneumonia and ventilator-associated tracheobronchitis; (3) non-inferiority multicenter randomized controlled trials comparing nebulized CMS to intravenous new cephalosporines/ß-lactamase inhibitors in patients with extensive drug-resistant GNB ventilator-associated pneumonia and ventilator-associated tracheobronchitis. This research received no external funding.
وصف الملف: application/pdf
اللغة: English
تدمد: 2076-2607
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3cffe23e108d0de3c7c94716d54edd3Test
http://europepmc.org/articles/PMC8227626Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....f3cffe23e108d0de3c7c94716d54edd3
قاعدة البيانات: OpenAIRE
الوصف
تدمد:20762607